The Company has initiated two pivotal animal studies for ARX828 and expects to receive results from these studies for analysis, by end of November.
The Company's goal is to develop ARX828 for the treatment of Rheumatoid Arthritis and Inflammatory Bowel Disease.
hopefully we're building up to a pop on good news..
hopefully we get a PR when they get the results..